Latest Aegerion Pharmaceuticals (AEGR) Headlines
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR
Business Wire - Tue Mar 11, 12:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq: AEGR) securities between March 15, 2012 and January 9, 2014.
Technical Pointers - Top Gainers: CEL-SCI, RadioShack, Penn West Petroleum, and Aegerion Pharma
PR Newswire - Mon Mar 10, 12:56PM CDT
On Friday, March 07, 2014, the US markets saw a mixed sentiment, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Cel-Sci Corporation (NYSE MKT: CVM), RadioShack Corporation (NYSE: RSH), Penn West Petroleum Ltd (NYSE: PWE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), which were amongst the top gainers for the session. Free research on these four companies can be accessed at:
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Aegerion Pharmaceuticals awards stock options to new employees
M2 - Mon Mar 10, 7:52AM CDT
US-based biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Friday the grant of stock options to purchase an aggregate of 51,750 common shares to 16 new employees under its inducement stock option programme.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aegerion Pharmaceuticals, Inc. to Contact Brower Piven Before the March 17, 2014 Lead Plaintiff Deadline -- AEGR
GlobeNewswire - Fri Mar 07, 6:17PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) securities during the period between March 15, 2012 and January 9, 2014, inclusive (the "Class Period").
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 07, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Fri Mar 07, 7:06AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on March 3, 2014, Aegerion granted stock options to purchase an aggregate of 51,750 shares of common stock to 16 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $54.25, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
LEAD PLAINTIFF DEADLINE: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline of March 17, 2014, Concerning Class Actions Against Aegerion Pharmaceuticals, Inc.
Business Wire - Thu Mar 06, 7:32PM CST
The Alexander Firm P.C., A Professional Law Corporation, reminds investors who purchased or acquired shares of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ: AEGR) between March 15, 2012 and January 9, 2014 (the "Class Period") that the deadline of March 17, 2014, is quickly approaching to move for Lead Plaintiff in the securities class actions filed on behalf of investors against the Company and certain of its officers.
The Zacks Analyst Blog Highlights:Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Why Isis Pharmaceuticals Continues to Impress
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
Over the past twelve months Isis Pharmaceuticals has been on a tear both at the deal table and in the market. At $51, Isis is still up more than 230% over the past twelve months. The company reported fourth quarter 2013 earnings...
Profit from Orphan Drugs: 3 Choices - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Mar 05, 1:18PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014
Business Wire - Tue Mar 04, 2:30PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) securities between March 15, 2012 and January 9, 2014.
EQUITY ALERT: Rosen Law Firm Reminds Aegerion Pharmaceuticals, Inc. Investors of Important March 17, 2014 Class Action Deadline -- AEGR
GlobeNewswire - Tue Mar 04, 11:30AM CST
The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the "Class Period") of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws.
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Aegerion Pharmaceuticals, Inc. Of Upcoming Deadline
Business Wire - Mon Mar 03, 5:09PM CST
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aegerion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEGR
GlobeNewswire - Sun Mar 02, 7:00AM CST
Pomerantz LLP has filed a class action lawsuit against Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10105, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Aegerion securities between March 15, 2012 and January 9, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:00AM CST
Another month in 2014 has drawn to a close -- as has another week of horrendous performances by several health-care stocks. February is the shortest month of the year, but its final week proved to be quite a long one for some investors. One of this...
Aegerion Pharmaceuticals Observes Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:55AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS) and Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR
Business Wire - Tue Mar 11, 12:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq: AEGR) securities between March 15, 2012 and January 9, 2014.
Technical Pointers - Top Gainers: CEL-SCI, RadioShack, Penn West Petroleum, and Aegerion Pharma
PR Newswire - Mon Mar 10, 12:56PM CDT
On Friday, March 07, 2014, the US markets saw a mixed sentiment, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Cel-Sci Corporation (NYSE MKT: CVM), RadioShack Corporation (NYSE: RSH), Penn West Petroleum Ltd (NYSE: PWE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), which were amongst the top gainers for the session. Free research on these four companies can be accessed at:
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Aegerion Pharmaceuticals awards stock options to new employees
M2 - Mon Mar 10, 7:52AM CDT
US-based biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Friday the grant of stock options to purchase an aggregate of 51,750 common shares to 16 new employees under its inducement stock option programme.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aegerion Pharmaceuticals, Inc. to Contact Brower Piven Before the March 17, 2014 Lead Plaintiff Deadline -- AEGR
GlobeNewswire - Fri Mar 07, 6:17PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) securities during the period between March 15, 2012 and January 9, 2014, inclusive (the "Class Period").
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 07, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Fri Mar 07, 7:06AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on March 3, 2014, Aegerion granted stock options to purchase an aggregate of 51,750 shares of common stock to 16 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $54.25, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
LEAD PLAINTIFF DEADLINE: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline of March 17, 2014, Concerning Class Actions Against Aegerion Pharmaceuticals, Inc.
Business Wire - Thu Mar 06, 7:32PM CST
The Alexander Firm P.C., A Professional Law Corporation, reminds investors who purchased or acquired shares of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ: AEGR) between March 15, 2012 and January 9, 2014 (the "Class Period") that the deadline of March 17, 2014, is quickly approaching to move for Lead Plaintiff in the securities class actions filed on behalf of investors against the Company and certain of its officers.
The Zacks Analyst Blog Highlights:Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Why Isis Pharmaceuticals Continues to Impress
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
Over the past twelve months Isis Pharmaceuticals has been on a tear both at the deal table and in the market. At $51, Isis is still up more than 230% over the past twelve months. The company reported fourth quarter 2013 earnings...
Profit from Orphan Drugs: 3 Choices - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Mar 05, 1:18PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014
Business Wire - Tue Mar 04, 2:30PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) securities between March 15, 2012 and January 9, 2014.
EQUITY ALERT: Rosen Law Firm Reminds Aegerion Pharmaceuticals, Inc. Investors of Important March 17, 2014 Class Action Deadline -- AEGR
GlobeNewswire - Tue Mar 04, 11:30AM CST
The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the "Class Period") of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws.
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Aegerion Pharmaceuticals, Inc. Of Upcoming Deadline
Business Wire - Mon Mar 03, 5:09PM CST
Rigrodsky & Long, P.A.:
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aegerion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEGR
GlobeNewswire - Sun Mar 02, 7:00AM CST
Pomerantz LLP has filed a class action lawsuit against Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10105, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Aegerion securities between March 15, 2012 and January 9, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:00AM CST
Another month in 2014 has drawn to a close -- as has another week of horrendous performances by several health-care stocks. February is the shortest month of the year, but its final week proved to be quite a long one for some investors. One of this...
Aegerion Pharmaceuticals Observes Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:55AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS) and Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.
